Latin America Research Stats
Applied Clinical Trials
Starting with Eastern European sites in the 1990s, companies have increasingly selected investigator sites outside of North America and Western Europe.
Starting with Eastern European sites in the 1990s, companies have increasingly selected investigator sites outside of North America and Western Europe. Recently, drug development organizations have also been recruiting sites and enrolling patients in more remote locations such as Asia, India, and Latin America. Little research has been done on the attitudes of investigators in these newer geographies: why they participate in clinical trial research, what they like and dislike about their clinical trial experiences, and their thoughts about organizations conducting these clinical studies. TTC and the University of the Sciences in Philadelphia conducted a 4,000 multinational site survey.
The overall response distribution in Latin America closely followed the distribution of sites by country and therapeutic areas recorded in ClinicalTrials.gov. The complete questionnaire and respondent answers can be found online.
Latin America and US investigators emphasize the importance of medical innovation as grounds for their involvement in clinical studies. For Latin American physicians, this interest in innovation holds whether the research directly touches their patients or not. Latin American investigators are especially keen to share their clinical trial derived knowledge with other physicians.
—TTC and the University of Sciences in Philadelphia (for more information, contact help@ttc-llc.com).
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
First Patient Dosed in Phase III Trial of Enhertu as First-Line Treatment for Endometrial Cancer
June 10th 2025In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair proficient primary advanced or recurrent endometrial cancer.
